Valuation dashboard for Adaptimmune Therapeutics plc (ADAP) with P/E N/A, P/B -0.18, EV/EBITDA -1.42 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets.
Analysis Summary
Adaptimmune Therapeutics plc reported revenue of $178.0M in the most recent fiscal year, growing at a 5-year CAGR of 175.5%.
Trailing-twelve-month margins: gross margin 83.9%, operating margin -362.7%, net margin -371.7%.
At the current price of $0.05, ADAP has negative trailing earnings (P/E not meaningful) and an ROE of 143.79%. Market capitalisation stands at $75M.
Balance sheet quality for ADAP: current ratio of 2.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -0.18 |
| EV / EBITDA | -1.42 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-3339.38 |
| vs Current Price | -6885428.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ADAP | Adaptimmune Therapeutics plc | $75M | 143.8% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.05 |
| Market Cap | $75M |
| Exchange | NASDAQ |
| Country | GB |
Profitability
| Return on Equity | 143.79% |
| Return on Invested Capital | -90.90% |
| Return on Assets | -59.65% |
| Gross Margin | 83.88% |
| Operating Margin | -362.66% |
| Net Margin | -371.74% |
Related companies: ANL · APLM · BLRX · ERNA · GOVX · LNAI · LPCN
Explore sector: Healthcare · Biotechnology
More sections of ADAP: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks